M Kahaleh, MD
Rheumatology · Toledo, OHNPI 1891781050
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boehringer Ingelheim at 39.4% of the total. Reporting peaked in 2019 at $7,382 and has fallen 94.4% since, to $416 in 2025.
Across 182 payments — averaging $93.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Actelion Pharmaceuticals US, Inc.$7K
- AbbVie$664
- Pfizer$599
- Amgen$442
- UCB, Inc.$389
- plus $2K from 14 others
Across 82 payments — averaging $7686.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$315K
- United Therapeutics Corporation$252K
- Boehringer Ingelheim$31K
- Genentech, Inc.$20K
- Sanofi US Services Inc.$8K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
What the payments were for
- Consulting fees$9,91058%
- Speaking & faculty fees$6164%
- Travel & lodging$2,06312%
- Food & beverage$4,31325%
- Education$1251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $6,702 |
| Actelion Pharmaceuticals US, Inc. | 10 | $6,583 |
| AbbVie | 22 | $664 |
| Pfizer | 39 | $599 |
| Amgen(2 entities) | 13 | $442 |
| UCB, Inc. | 4 | $389 |
| GSK | 4 | $275 |
| E.r. Squibb & Sons, L.L.C. | 4 | $250 |
| Johnson & Johnson | 42 | $249 |
| AstraZeneca(2 entities) | 7 | $157 |
| Lilly USA, LLC | 4 | $120 |
| Novartis | 7 | $113 |
| Genentech USA, Inc. | 3 | $110 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $103 |
| Janssen Scientific Affairs, LLC | 1 | $87 |
| United Therapeutics Corporation | 3 | $79 |
| Fresenius Kabi USA, LLC | 1 | $33 |
| CSL Behring | 1 | $30 |
| Celltrion USA Inc. | 1 | $22 |
| Octapharma USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,027 in reported general payments places this provider in the 85th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 84 | $698,845 |
| Enbrel SureclickEtanercept | 96 | $695,753 |
| Xeljanz XrTofacitinib Citrate | 79 | $443,775 |
| Orencia ClickjectAbatacept | 22 | $175,020 |
| OrenciaAbatacept | 29 | $159,440 |
| Humira(Cf)Adalimumab | 11 | $140,058 |
| RinvoqUpadacitinib | 22 | $137,294 |
| Ambrisentan | 22 | $106,019 |
| EnbrelEtanercept | 14 | $103,999 |
| Humira PenAdalimumab | 12 | $73,468 |
| MethotrexateMethotrexate Sodium | 663 | $16,095 |
| SavellaMilnacipran Hcl | 14 | $10,135 |
| Pilocarpine Hcl | 93 | $9,800 |
| RestasisCyclosporine | 14 | $8,717 |
| Leflunomide | 150 | $8,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Savella, Restasis | $664 | $296,20461 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $250 | $159,44029 claims |
| AmgenEnbrel | $442 | $103,99914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Toledo
- Aaron PumerantzToledo$11K
- Nezam AltorokToledo$10K
- Leonard CalabreseCleveland$1.9M
- Gregory DelorenzoCincinnati$1.3M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
- Chacko AlappattMiamisburg$258K
- Adam BrownCleveland$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.